Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
09 2021
Historique:
received: 03 11 2020
revised: 17 03 2021
accepted: 29 04 2021
pubmed: 6 7 2021
medline: 19 2 2022
entrez: 5 7 2021
Statut: ppublish

Résumé

A small proportion of patients with chronic obstructive pulmonary disease (COPD) patients present severe pulmonary hypertension (PH), defined by mean pulmonary artery pressure (mPAP) ≥35 mm Hg measured by right heart catheterization. Little is known about the characteristics of severe PH-COPD. The aim of the study based on a national registry was to describe this phenotype. We prospectively included and followed patients with incident PH-COPD. Clinical, functional, hemodynamic data at inclusion and follow-up were retrieved. Survival assessed by Kaplan-Meier analysis was the primary end-point. From 2012 to 2016, 99 patients from 13 French centers were included in the study (82 males; median age 66.0 years [interquartile range 62.0-72.0]). At inclusion, most patients had marked dyspnea (55.6% and 22.2% New York Heart Association class III and IV, respectively). During 12 months before inclusion, 42.9% had an exacerbation requiring a hospitalization. Pulmonary function tests showed a moderate obstructive pattern with median (interquartile range) FEV Severe PH-COPD is characterized by moderate airway obstruction but marked dyspnea and marked hypoxemia, low DLCO and high mPAP. This phenotype is associated with poor prognosis.

Sections du résumé

BACKGROUND
A small proportion of patients with chronic obstructive pulmonary disease (COPD) patients present severe pulmonary hypertension (PH), defined by mean pulmonary artery pressure (mPAP) ≥35 mm Hg measured by right heart catheterization. Little is known about the characteristics of severe PH-COPD. The aim of the study based on a national registry was to describe this phenotype.
METHODS
We prospectively included and followed patients with incident PH-COPD. Clinical, functional, hemodynamic data at inclusion and follow-up were retrieved. Survival assessed by Kaplan-Meier analysis was the primary end-point.
RESULTS
From 2012 to 2016, 99 patients from 13 French centers were included in the study (82 males; median age 66.0 years [interquartile range 62.0-72.0]). At inclusion, most patients had marked dyspnea (55.6% and 22.2% New York Heart Association class III and IV, respectively). During 12 months before inclusion, 42.9% had an exacerbation requiring a hospitalization. Pulmonary function tests showed a moderate obstructive pattern with median (interquartile range) FEV
CONCLUSIONS
Severe PH-COPD is characterized by moderate airway obstruction but marked dyspnea and marked hypoxemia, low DLCO and high mPAP. This phenotype is associated with poor prognosis.

Identifiants

pubmed: 34218966
pii: S1053-2498(21)02307-X
doi: 10.1016/j.healun.2021.04.021
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1009-1018

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Gaëlle Dauriat (G)

Service de pneumologie B, hôpital Bichat, Paris, France, Université Paris 7, Inserm UMR1152.

Martine Reynaud-Gaubert (M)

Service de pneumologie, hôpital Nord, Marseille, France.

Vincent Cottin (V)

Service de pneumologie hôpital Louis Pradel, Lyon, France.

Bouchra Lamia (B)

Service de pneumologie, Normandie Université, UNIROUEN, EA 3830. CHU de Rouen et Groupe Hospitalier du Havre, France.

David Montani (D)

Service de pneumologie, hôpital Bicêtre; Le Kremlin Bicêtre, France; Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Mathieu Canuet (M)

Service de pneumologie, Nouvel Hôpital Civil, Strasbourg, France.

Clement Boissin (C)

Service de pneumologie, hôpital Arnaud de Villeneuve, Montpellier, France.

Cecile Tromeur (C)

Service de pneumologie, hôpital de la cavale blanche, Brest, France.

Ari Chaouat (A)

Service de pneumologie, hôpital Brabois, Nancy, France.

Bruno Degano (B)

Service de pneumologie, hôpital Albert Michalon, Grenoble, France.

Emmanuel Bergot (E)

Service de pneumologie, hôpital côte de nacre, Caen France.

Olivier Sanchez (O)

Service de pneumologie, hôpital européen Georges Pompidou, Paris, France.

Gregoire Prevot (G)

Service de pneumologie, hôpital Larrey, Toulouse, France.

Olivier Sitbon (O)

Service de pneumologie, hôpital Bicêtre; Le Kremlin Bicêtre, France; Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Gabriel Thabut (G)

Service de pneumologie B, hôpital Bichat, Paris, France, Université Paris 7, Inserm UMR1152.

Drifa Belhadi (D)

Unité de recherche clinique, hôpital Bichat, Paris, France.

Yolande Costa de Beauregard (YC)

Centre d'investigation clinique, hôpital Bichat, Paris, France.

Amina Bencherif (A)

Centre d'investigation clinique, hôpital Bichat, Paris, France.

Marc Humbert (M)

Service de pneumologie, hôpital Bicêtre; Le Kremlin Bicêtre, France; Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Gerald Simonneau (G)

Service de pneumologie, hôpital Bicêtre; Le Kremlin Bicêtre, France; Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Cedric Laouenan (C)

Unité de recherche clinique, hôpital Bichat, Paris, France.

Hervé Mal (H)

Service de pneumologie B, hôpital Bichat, Paris, France, Université Paris 7, Inserm UMR1152. Electronic address: herve.mal@bch.aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH